Mitch K. Goldenberg
Direttore Tecnico/Scientifico/R&S presso CONCERT PHARMACEUTICALS, INC.
Provenienza dei contatti di primo grado di Mitch K. Goldenberg
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Private Company | Pharmaceuticals: Major | 32 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Mitch K. Goldenberg tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
Cowen & Co. LLC
 Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Investment Banks/Brokers | Director/Board Member | |
| CITIGROUP INC. | Major Banks | Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO | |
Santarus, Inc.
 Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| CYTOKINETICS, INCORPORATED | Pharmaceuticals: Major | Director/Board Member | |
Faraday Pharmaceuticals, Inc. (Washington)
 Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Drugstore Chains | Corporate Officer/Principal Corporate Officer/Principal | |
| ALEXZA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| TETRAPHASE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Patara Pharma LLC
 Patara Pharma LLC Pharmaceuticals: MajorHealth Technology Patara Pharma LLC provides biotechnology solutions. It develops biopharmaceutical therapy for the treatment of allergic and inflammatory diseases and conditions that affect orphan patient populations. The company was founded by William Gerhart, Pravin Soni and Ahmet Tutuncu in 2013 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
SRI International
 SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| Dartmouth College | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Stifel, Nicolaus & Co., Inc.
 Stifel, Nicolaus & Co., Inc. Investment Banks/BrokersFinance Stifel, Nicolaus & Co., Inc. (Stifel) is a dual-registered broker-dealer and investment adviser headquartered in St. Louis, Missouri. Founded in 1890, the firm is a subsidiary of Stifel Financial Corp. (NYSE: SF), a financial service holding company. Stifel provides full-service brokerage and investment advisory services to individuals and their families, institutions and businesses, and financial advisors. | Investment Banks/Brokers | Analyst-Equity | |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Boston University | College/University | Graduate Degree Undergraduate Degree | |
Aptiv Services US LLC
 Aptiv Services US LLC Auto Parts: OEMProducer Manufacturing Aptiv Services US LLC manufactures automotive components. The firm provides such as chassis, engine steering, thermal, controls & security systems, electrical/electronic architecture, in-car entertainment technologies and electrical products. The company is headquartered in Troy, MI. | Auto Parts: OEM | Corporate Officer/Principal | |
| XENOPORT, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| OCERA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
| Babson College | College/University | Undergraduate Degree Masters Business Admin | |
| Bucknell University | College/University | Undergraduate Degree | |
| Rutgers State University of New Jersey | College/University | Doctorate Degree | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Undergraduate Degree Undergraduate Degree | |
| University of South Carolina | College/University | Undergraduate Degree | |
APEIRON Biologics AG
 APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Biotechnology | Director/Board Member | |
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
TVM Capital Healthcare Partners Ltd. /SG/
 TVM Capital Healthcare Partners Ltd. /SG/ Investment ManagersFinance Tvm Capital Healthcare Partners Pte Ltd. operates as a healthcare private equity investor. The company is headquartered in Singapore. | Investment Managers | Chief Executive Officer | |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Wisconsin | College/University | Doctorate Degree | |
Quadriga BioSciences, Inc.
 Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Pharmaceuticals: Major | Director/Board Member | |
| Darla Moore School of Business | College/University | Masters Business Admin | |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Biotechnology | Director of Finance/CFO | |
| JANUX THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| ENGENE HOLDINGS INC. | Biotechnology | Director of Finance/CFO | |
F-star Biotechnology Ltd.
 F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Robert W. Baird & Co., Inc.
 Robert W. Baird & Co., Inc. Investment ManagersFinance Robert W. Baird & Co., Inc. operates as a wealth management, capital markets, private equity and asset management firm. It offers equity research, corporate restructuring, mergers and acquisitions, public financing and fixed income services. The firm serves individual, corporate, institutional and municipal clients. The company was founded by Robert Wilson Baird in 1919 and is headquartered in Milwaukee, WI. | Investment Managers | Corporate Officer/Principal | |
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Pharmaceuticals: Major | Chief Executive Officer | |
F-star Alpha Ltd.
 F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
| AMECO MEDICAL INDUSTRIES | Medical Specialties | Director/Board Member | |
F-Star Beta Ltd.
 F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
| Parke-Davis Pharmaceutical Research, Inc. | Chief Tech/Sci/R&D Officer | ||
| ANACOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 39 |
| Regno Unito | 5 |
| Austria | 3 |
| Francia | 2 |
| Singapore | 2 |
Settori
| Health Technology | 30 |
| Consumer Services | 10 |
| Finance | 6 |
| Commercial Services | 3 |
| Retail Trade | 2 |
Posizioni
| Director/Board Member | 126 |
| Corporate Officer/Principal | 78 |
| Independent Dir/Board Member | 42 |
| Undergraduate Degree | 25 |
| Chairman | 20 |
Contatti più connessi
| Insiders | |
|---|---|
| Douglas Cole | 44 |
| John Freund | 37 |
| Meghan Fitzgerald | 28 |
| Helmut Schühsler | 28 |
| Wendell Wierenga | 23 |
| Jesper Høiland | 12 |
| Jeffrey S. Williams | 11 |
| Nancy Stuart | 10 |
| Christine van Heek | 9 |
| Thomas G. Auchincloss | 9 |
| Marc A. Becker | 9 |
| Ryan Daws | 9 |
| Ronald W. Barrett | 9 |
| Ian Robert Silverman | 8 |
| Justine E. Koenigsberg | 7 |
- Borsa valori
- Insiders
- Mitch K. Goldenberg
- Connessioni Società
